Add like
Add dislike
Add to saved papers

Cost-Sensitive Weighted Contrastive Learning Based on Graph Convolutional Networks for Imbalanced Alzheimer's Disease Staging.

Identifying the progression stages of Alzheimer's disease (AD) can be considered as an imbalanced multi-class classification problem in machine learning. It is challenging due to the class imbalance issue and the heterogeneity of the disease. Recently, graph convolutional networks (GCNs) have been successfully applied in AD classification. However, these works did not handle the class imbalance issue in classification. Besides, they ignore the heterogeneity of the disease. To this end, we propose a novel cost-sensitive weighted contrastive learning method based on graph convolutional networks (CSWCL-GCNs) for imbalanced AD staging using resting-state functional magnetic resonance imaging (rs-fMRI). The proposed method is developed on a multi-view graph constructed using the functional connectivity (FC) and high-order functional connectivity (HOFC) features of the subjects. A novel cost-sensitive weighted contrastive learning procedure is proposed to capture discriminative information from the minority classes, encouraging the samples in the minority class to provide adequate supervision. Considering the heterogeneity of the disease, the weights of the negative pairs are introduced into contrastive learning and they are computed based on the distance to class prototypes, which are automatically learned from the training data. Meanwhile, the cost-sensitive mechanism is further introduced into contrastive learning to handle the class imbalance issue. The proposed CSWCL-GCN is evaluated on 720 subjects (including 184 NCs, 40 SMC patients, 208 EMCI patients, 172 LMCI patients and 116 AD patients) from the ADNI (Alzheimer's Disease Neuroimaging Initiative). Experimental results show that the proposed CSWCL-GCN outperforms state-of-the-art methods on the ADNI database.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app